Voyager Competitors

Stocks . USA . 
Stock . Voyager Therapeutics
VYGR Stock  USD 5.75  0.06  1.05%   
Voyager Therapeutics competes with Fate Therapeutics, Sana Biotechnology, Caribou Biosciences, Arcus Biosciences, and Karyopharm Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Voyager Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Voyager Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Voyager Therapeutics Correlation with its peers.
To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Voyager Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.135.7611.39
Details
Intrinsic
Valuation
LowRealHigh
1.977.6013.23
Details
Naive
Forecast
LowNextHigh
0.105.1410.77
Details
10 Analysts
Consensus
LowTargetHigh
12.4413.6715.17
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Voyager Therapeutics. Your research has to be compared to or analyzed against Voyager Therapeutics' peers to derive any actionable benefits. When done correctly, Voyager Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Voyager Therapeutics.

Voyager Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Voyager Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Voyager and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Voyager Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
HOOK
+ 0.93
SANA
SANA
+ 0.87
FATE
HOOK
+ 0.79
FATE
KPTI
+ 0.4
SANA
KPTI
+ 0.38
CRBU
HOOK
+ 0.36
KPTI
  
High negative correlations   
XFOR
- 0.39
KPTI
CRBU
- 0.13
SANA
CRBU
- 0.06
FATE
XFOR
- 0.04
CRBU

Risk-Adjusted Indicators

There is a big difference between Voyager Stock performing well and Voyager Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Voyager Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Voyager Therapeutics Competitive Analysis

The better you understand Voyager Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Voyager Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Voyager Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
VYGR FATE SANA CRBU RCUS KPTI XFOR HOOK
 1.05 
 5.75 
Voyager
 1.20 
 1.68 
Fate
 3.12 
 1.65 
Sana
 0.55 
 1.80 
Caribou
 0.26 
 15.50 
Arcus
 0.78 
 0.63 
Karyopharm
 0.16 
 0.61 
XFOR
 5.61 
 2.02 
Hookipa
Market Volatility
(90 Days Market Risk)
Moderately volatile
Very risky
Very risky
Dangerous
Somewhat reliable
Very risky
Out of control
Very risky
Market Performance
(90 Days Performance)
Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Insignificant
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Quite High
Very High
Average
Low
Very High
Very High
Above Average
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Buy
Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Hold
Hold
Strong Sell
Strong Sell
Strong Sell
Hold
Cautious Hold
Current Ratio
1.55 X
6.55 X
5.09 X
12.23 X
6.22 X
3.88 X
2.39 X
5.48 X
Net Asset
351.28 M
506.22 M
565.3 M
432.21 M
1.09 B
240.44 M
147.26 M
161.34 M
Profit Margin
0.16 %
N/A
N/A
N/A
(1.03) %
(0.59) %
31.32 %
(0.93) %
EBITDA
126.45 M
(172.23 M)
(252.39 M)
(112.53 M)
(283 M)
(118.42 M)
(107.52 M)
(77.34 M)
Operating Margin
(0.56) %
(17.04) %
N/A
(16.67) %
(2.19) %
(0.68) %
(60.21) %
(17.37) %
Current Valuation
14.36 M
(5.46 M)
265.47 M
(38.99 M)
387.43 M
142.09 M
47.65 M
(32.57 M)
Price To Book
0.95 X
0.53 X
1.26 X
0.58 X
2.51 X
12.05 X
1.75 X
0.34 X
Retained Earnings
(261.18 M)
(1.21 B)
(1.34 B)
(299.29 M)
(849 M)
(1.49 B)
(477.9 M)
(369.26 M)
Current Asset
195.89 M
47.4 M
N/A
N/A
N/A
130.25 M
N/A
26.61 M
Beta
0.89
1.88
1.44
2.26
0.89
0.15
0.39
0.83
Number Of Employees
162
181
328
158
577
325
127
151
Shares Outstanding
54.63 M
113.89 M
223.27 M
90.55 M
91.51 M
126.19 M
170.55 M
9.66 M
Cash Flow From Operations
77.92 M
(132.26 M)
(253.58 M)
(93.29 M)
(306 M)
(92.72 M)
(96.51 M)
(57.52 M)
Total Debt
20.29 M
103.54 M
104.1 M
27.11 M
11 M
177.02 M
58.28 M
6.56 M
Return On Equity
0.1
-0.47
-0.93
-0.44
-0.5
-8.91
0.22
-0.49
Return On Asset
0.0157
-0.22
-0.31
-0.25
-0.15
-0.34
-0.4
-0.2
Number Of Shares Shorted
2.56 M
11.35 M
35.15 M
8.62 M
8.03 M
18.92 M
12.5 M
45.02 K
Book Value Per Share
6.06 X
3.18 X
1.31 X
3.10 X
6.17 X
(1.27) X
0.30 X
7.45 X
Current Liabilities
23.93 M
14.68 M
N/A
N/A
N/A
14.95 M
N/A
25.01 M
Total Asset
351.28 M
506.22 M
565.3 M
432.21 M
1.09 B
240.44 M
147.26 M
161.34 M
Debt To Equity
0.40 %
0.19 %
0.18 %
0.08 %
0.17 %
2.59 %
1.28 %
0.05 %
Short Ratio
4.44 X
3.10 X
20.07 X
4.55 X
10.60 X
19.48 X
8.64 X
1.08 X
Target Price
17.1
6.31
9.4
12.5
33.2
4.5
3.05
23.5
Shares Owned By Institutions
65.50 %
97.83 %
92.45 %
62.48 %
60.07 %
48.20 %
67.66 %
37.16 %
Market Capitalization
314.1 M
191.34 M
368.39 M
162.99 M
1.42 B
80.13 M
104.25 M
24.35 M
Price To Earning
5.62 X
(4.35) X
N/A
N/A
27.69 X
(3.90) X
N/A
12.06 X
Price To Earnings To Growth
N/A
N/A
N/A
0.50 X
N/A
(0.15) X
N/A
(0.19) X
Price To Sales
1.92 X
14.23 X
N/A
14.20 X
5.39 X
0.54 X
185.18 X
0.47 X
Net Income
132.33 M
(160.93 M)
(283.25 M)
(102.07 M)
(307 M)
(143.1 M)
(101.17 M)
(81.58 M)
Earnings Per Share
0.66 X
(1.64) X
(1.40) X
(1.66) X
(3.19) X
(1.05) X
(0.08) X
(3.67) X
Shares Owned By Insiders
16.98 %
2.17 %
8.63 %
10.03 %
38.80 %
6.21 %
1.14 %
21.43 %
Revenue
250.01 M
63.53 M
N/A
34.48 M
117 M
146.03 M
N/A
20.13 M
Working Capital
255.18 M
292.45 M
149.03 M
310.54 M
647 M
164.44 M
99.21 M
105.13 M
Cash And Equivalents
148.06 M
568.85 M
484.8 M
339.92 M
1.05 B
170.85 M
47.38 M
117.92 M
Cash Per Share
3.83 X
5.86 X
2.57 X
5.59 X
14.48 X
2.14 X
0.69 X
2.16 X
Gross Profit
(19.86 M)
(224.15 M)
N/A
(68.38 M)
(176 M)
151.86 M
3 M
(52.97 M)
Day Typical Price
5.72
1.71
1.64
1.81
15.53
0.64
0.62
2.05
Accumulation Distribution
0.0579
0.0889
0.0988
0.0538
0.0557
0.0455
0.16
0.0654
Market Facilitation Index
0.34
0.16
0.17
0.1
0.89
0.03
0.11
0.14
Daily Balance Of Power
0.1765
0.125
0.2941
(0.10)
0.0449
(0.17)
0.0091
(0.86)
Period Momentum Indicator
0.06
0.02
0.05
(0.01)
0.04
(0.01)
0.001
(0.12)
Rate Of Daily Change
1.01
1.01
1.03
0.99
1.0
0.99
1.0
0.94
Day Median Price
5.7
1.72
1.64
1.81
15.55
0.65
0.63
2.07
Price Action Indicator
0.08
(0.03)
0.04
(0.01)
(0.03)
(0.01)
(0.01)
(0.11)
Coefficient Of Variation
81032.38
(599.24)
(408.19)
(5,336)
(6,488)
(4,473)
2207.18
(328.27)
Mean Deviation
3.62
5.11
4.37
3.62
2.7
3.06
6.72
2.92
Jensen Alpha
(0.07)
(1.17)
(1.44)
(0.16)
(0.11)
(0.14)
0.5077
(1.22)
Total Risk Alpha
(0.16)
(1.29)
(1.56)
(0.24)
(0.17)
(0.25)
0.1958
(1.32)
Sortino Ratio
(0)
N/A
N/A
N/A
N/A
N/A
0.0381
N/A
Downside Variance
27.39
N/A
N/A
N/A
N/A
N/A
176.56
N/A
Standard Deviation
5.56
6.57
5.67
4.91
3.65
4.86
11.89
3.94
Kurtosis
4.62
0.5849
0.7509
1.04
0.6267
4.66
8.95
1.92
Potential Upside
9.47
11.34
9.02
8.22
7.43
8.97
13.85
6.85
Treynor Ratio
(0)
(0.41)
(0.73)
(0.04)
(0.04)
(0.15)
0.5564
(1.78)
Maximum Drawdown
36.72
34.46
28.04
28.53
17.22
26.95
67.48
22.36
Variance
30.87
43.13
32.17
24.08
13.33
23.63
141.42
15.5
Market Risk Adjusted Performance
0.009
(0.40)
(0.72)
(0.03)
(0.03)
(0.14)
0.5664
(1.77)
Risk Adjusted Performance
0.0096
(0.12)
(0.19)
(0.01)
(0)
(0.01)
0.0452
(0.23)
Skewness
0.6542
0.6745
0.5194
(0.1)
0.0591
1.71
(0.15)
(0.37)
Semi Deviation
4.92
N/A
N/A
N/A
N/A
N/A
10.68
N/A
Information Ratio
(0)
(0.17)
(0.25)
(0.03)
(0.02)
(0.03)
0.0426
(0.31)
Value At Risk
(7.03)
(10.11)
(9.84)
(8.21)
(6.29)
(5.56)
(13.51)
(6.67)
Expected Short fall
(3.99)
N/A
N/A
N/A
N/A
N/A
(8.46)
N/A
Downside Deviation
5.23
N/A
N/A
N/A
N/A
N/A
13.29
N/A
Semi Variance
24.25
N/A
N/A
N/A
N/A
N/A
113.97
N/A

Voyager Therapeutics Competition Performance Charts

Five steps to successful analysis of Voyager Therapeutics Competition

Voyager Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Voyager Therapeutics in relation to its competition. Voyager Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Voyager Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Voyager Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Voyager Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Voyager Therapeutics position

In addition to having Voyager Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Entertainment Thematic Idea Now

Entertainment
Entertainment Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Entertainment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Voyager Stock Analysis

When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY